Cargando…

Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer

We aim to identify predictors of therapy-related myeloid neoplasms (t-MN) in patients with breast cancer (BC) and cytopenias to determine the timing of bone marrow biopsy (BMBx). Patients with BC and cytopenias who were referred for BMBx between 2002-2018 were identified using the Memorial Sloan Ket...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrone, Giulia, Gaulin, Charles, Derkach, Andriy, Kishtagari, Ashwin, Robson, Mark E., Parameswaran, Rekha, Stein, Eytan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Myelodysplastic Syndromes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827166/ https://www.ncbi.nlm.nih.gov/pubmed/35770528 http://dx.doi.org/10.3324/haematol.2021.280437

Ejemplares similares

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms
por: Badar, Talha, et al.
Publicado: (2023)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
por: Karantanos, Theodoros, et al.
Publicado: (2022)

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
por: Teichman, Jennifer, et al.
Publicado: (2022)

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes
por: Fischer, Melissa A., et al.
Publicado: (2022)

Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation
por: Muto, Tomoya, et al.
Publicado: (2023)

Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry
por: Clichet, Valentin, et al.
Publicado: (2023)

Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes
por: Taran, Sachi Jain, et al.
Publicado: (2015)

High-risk MDS after HMAs
por: Adès, Lionel
Publicado: (2019)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
por: Feld, Jonathan, et al.
Publicado: (2020)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021)

Immunogenicity of Covid-19 Vaccination in Subjects with Myelodysplastic Syndromes
por: Vidler, Jennifer, et al.
Publicado: (2021)

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study
por: Savona, Michael R., et al.
Publicado: (2021)

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

Incidence and Burden of the Myelodysplastic Syndromes
por: Cogle, Christopher R.
Publicado: (2015)

Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
por: Bejar, Rafael
Publicado: (2015)

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2017)

Gender differences in clinical, laboratory and polysomnographic features of restless legs syndrome
por: Holzknecht, Evi, et al.
Publicado: (2019)

Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren’s syndrome
por: Broeren, Mathijs G A, et al.
Publicado: (2022)

Weight change over five-year periods and number of components of the metabolic syndrome in a Dutch cohort
por: Bot, M., et al.
Publicado: (2010)

Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome
por: Jie, Kim E, et al.
Publicado: (2010)

Syndrome in Question()
por: Orasmo, Cínthia Rosane, et al.
Publicado: (2014)

Syndrome in Question()
por: Meireles, Sheila Itamara Ferreira do Couto, et al.
Publicado: (2014)

Syndrome in question*
por: Wu, Yinhua, et al.
Publicado: (2014)

Do you know this syndrome?()
por: Frainer, Renata Hubner, et al.
Publicado: (2013)

Do you know this syndrome?
por: Gontijo, Gabriela Maria Abreu
Publicado: (2013)

Do you know this syndrome?*
por: Silveira, Laura Maria Andrade, et al.
Publicado: (2013)

Do you know this syndrome?
por: Kondo, Rogerio Nabor, et al.
Publicado: (2013)

Do you know this syndrome?()
por: Meotti, Carolina Degen, et al.
Publicado: (2013)

Do you know this syndrome?()
por: de Lima, Alexandre Moretti, et al.
Publicado: (2013)

Do you know this syndrome?
por: Santos, Guida, et al.
Publicado: (2013)

Do you know this syndrome?
por: Machado, Pedro Vale, et al.
Publicado: (2013)

Syndrome In Question
por: do Nascimento, Ana Cláudia Mendes, et al.
Publicado: (2014)

Syndrome In Question
por: Lavorato, Fernanda Guedes, et al.
Publicado: (2014)

Syndrome in Question()
por: Santos, Guida, et al.
Publicado: (2014)

Syndrome in Question()
por: Tonolli, Vanessa Mello, et al.
Publicado: (2014)

Syndrome in question
por: Peruzzo, Juliano, et al.
Publicado: (2015)

De novo, heterozygous, loss‐of‐function mutations in SYNGAP1 cause a syndromic form of intellectual disability
por: Parker, Michael J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s6a24r9vnc6lj8jlk4uvodeljk